Patients on Itovebi plus Ibrance and fulvestrant had improved progression-free and overall survival compared to Ibrance-fulvestrant alone.

Androgen deprivation therapy (ADT) has long been a foundation in the management of prostate cancer. Since the introduction of ...

Men on active surveillance for low- to intermediate-risk prostate cancer (PCa) have low risk for PCa-related mortality at a median follow-up of 18 years. However, a majority of men do progress and ...

With an estimated 1.5 million new cases and 397,000 deaths worldwide, prostate cancer is the world's second most frequent ...

Q2 2025 Earnings Call Transcript July 21, 2025 Operator: Good morning and good afternoon, and welcome to the Novartis Q2 2025 ...

Novartis AG (NYSE:NVS) is a Swiss pharmaceutical leader focused on developing innovative treatments across oncology, ...

Jacob E. Berchuck, MD, highlights novel findings pointing to androgen receptor signaling and Wnt pathway activation as key ...

Once seen as a niche tool for rare tumors, theranostics is quickly becoming a new standard in cancer care. Combining diagnostics and therapy in a single platform, the field has drawn billions in ...

Company touted Kisqali's "replacement power" as another blockbuster faces generic competition and expressed optimism about ...

Novartis is launching a $10 billion share buyback to be completed by year-end 2027 as new drug launches accelerate. | ...

The pharmaceutical company raised its full-year profit guidance after continued demand for key drugs fueled growth in second-quarter sales and earnings.

Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.